Evidence map›Paper›PMID 29245946›Full record

ArticleOncotarget2017

MiR-483-5p promotes IGF-II transcription and is associated with poor prognosis of hepatocellular carcinoma.

Shaohui Tang, Yanfang Chen, Shufen Feng, Tingzhuang Yi, Xuyou Liu, Qiang Li, Zhilong Liu, Cuiping Zhu, Jianjun Hu, Xi Yu and 8 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. High expression of IGF2-derived intronic miR-483 predicts outcome in hepatoblastoma.Cancer biomarkers : section A of Disease markers · 2020
    Observational
  18. Article
  19. The Glucose-RegulatedCancers · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Shaohui TangDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Yanfang ChenDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Shufen FengDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Tingzhuang YiDepartment of Gastroenterology, Affiliated Hospital of Youjiang Medical University for Nationlities, Baise, Guangxi, China.
Xuyou LiuDepartment of Gastroenterology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
Qiang LiDepartment of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Zhilong LiuDepartment of General Surgery, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Cuiping ZhuDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Jianjun HuDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Xi YuDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Min WangDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Guoli CaoDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Hui TangClinical Medicine Research Institute, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Caiqun BieDepartment of Gastroenterology, The Affiliated Shenzhen Shajing Hospital, Guangzhou Medical University, Shenzhen, Guangdong, China.
Feng MaDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Huijun TangDepartment of Gastroenterology, The Affiliated Shenzhen Shajing Hospital, Guangzhou Medical University, Shenzhen, Guangdong, China.
Gang DuClinical Medicine Research Institute, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong, China.
Jianwei HuangDepartment of Gastroenterology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
First Affiliated Hospital of Jinan University · CNGuangzhou Medical University · CNShenzhen Shajing Affiliated Hospital of Guangzhou Medical University · CNAffiliated Hospital of Youjiang Medical University for Nationalities · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human insulin-like growth factor-II (IGF-II) gene transcribes four mRNAs (P1 mRNA-P4 mRNA), and P3 mRNA overexpression contributes to hepatocarcinogenesis. IGF-II-derived miR-483-5p is implicated in the development of cancers. Here, we investigated the involvement of miR-483-5p in P3 mRNA overexpression regulation and its role in hepatocellular carcinoma. Our results showed that miR-483-5p up-regulated P3 mRNA transcription by targeting the 5'-untranslated region (5'UTR) of P3 mRNA in hepatocellular carcinoma. The mechanism was involved in recruiting of an argonaute 1(Ago1)-argonaute 2 (Ago2) complex to the P3 mRNA 5'UTR and the P3 promoter of IGF-II gene by miR-483-5p, accompanied by increased enrichment of RNA polymerase II and activating histone marks histone 3 lysine 4 trimethylation (H3K4me3), histone 3 lysine 27 acetylation (H3K27ac), and histone 4 lysine 5/8/12/16 acetylation (H4Kac) at the P3 promoter. High miR-483-5p expression was an independent predictor for shorter survival of HCC patients. The findings suggest that miR-483-5p promotes P3 mRNA transcription by recruiting the Ago1-Ago2 complex to the P3 mRNA 5'UTR and is associated with poor prognosis of HCC. Our results display a potential new model for miRNAs to up-regulate gene expression.

Indexed as

ago proteinsinferior clinical outcomeliver cancermiRNAstranscription regulation

Identifiers

PMID29245946
PMCPMC5725137
OpenAlexW2762589035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.